Eton Pharmaceuticals officer proposes $229K share sale

The notice also reports 25,000 common shares sold on August 24, 2026, for $1,625,783.03 in gross proceeds.

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. officer David Krempa reported a proposed sale of 4,166 common shares, with an aggregate market value of $229,406.21, for October 6, 2026, through Raymond James & Associates. The notice says the sale is to cover RSU vesting and lists 10,522 common shares acquired from the issuer through an RSU vest on October 2, 2026.

Key Figures

Proposed sale: 4,166 common shares Aggregate market value: $229,406.21 Common shares acquired through RSU vest: 10,522 shares +2 more

5 metrics

Proposed sale 4,166 common shares Approximate sale date: October 6, 2026

Aggregate market value $229,406.21 Proposed sale of common shares

Common shares acquired through RSU vest 10,522 shares October 2, 2026; acquired from the issuer

Shares sold in prior three months 25,000 common shares Sale date: August 24, 2026

Gross proceeds $1,625,783.03 Sale of 25,000 common shares on August 24, 2026

Key Terms

RSU Vest, Sell to Cover, Rule 144

3 terms

RSU Vest financial

"RSU Vest"

Sell to Cover financial

"Sell to Cover for RSU vesting."

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ETON shares did David Krempa plan to sell?

David Krempa, an officer of Eton Pharmaceuticals, reported a proposed sale of 4,166 common shares with an aggregate market value of $229,406.21 for October 6, 2026, through Raymond James & Associates. The notice says the sale is to cover RSU vesting.

How many ETON shares did David Krempa sell in the prior three months?

The notice lists 25,000 common shares sold on August 24, 2026, for $1,625,783.03 in gross proceeds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:05 PM Accepted by SEC EDGAR 10/06/2026 - 04:05 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001968254
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Eton Pharmaceuticals, Inc.
SEC File Number	001-38738
Address of Issuer	21925 W. FIELD PARKWAY SUITE 235 DEER PARK ILLINOIS 60010-7278
Phone	(847) 787-7361
Name of Person for Whose Account the Securities are To Be Sold	Krempa David
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates Inc. 880 Carillon Parkway St. Petersburg FL 33716	4166	229406.21	28580000	10/06/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/02/2026	RSU Vest	Issuer			10522	10/06/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Krempa 4101 W Mullen Ave Tampa FL 33609	Common	08/24/2026	25000	1625783.03

144: Remarks and Signature

Remarks	Sell to Cover for RSU vesting.
Date of Notice	10/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Rashida Mitchell, as duly authorized representative of Raymond James & Associates, Inc., as attorney-in-fact for David Krempa
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)